| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 225,033 | 216,236 |
| Net increase in cash, cash equivalents and restricted cash | 158,308 | 173,725 |
| Cash and cash equivalents at beginning of period | 141,636 | - |
| Cash and cash equivalents at end of period | 299,944 | - |
Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. (TSHA)